The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

reboundtx.com

Stage

Spinoff / Spinout

Total Raised

$20.26M

Investors Count

4

Deal Terms

2

Portfolio Exits

1

Rebound Therapeutics Funding, Rebound Therapeutics Valuation & Rebound Therapeutics Revenue

3 Fundings

Rebound Therapeutics's latest funding round was a Acquired for on September 9, 2019.

Rebound Therapeutics's valuation in July 2017 was $44.45M.

Rebound Therapeutics's latest post-money valuation is from July 2017.

Sign up for a free trial to see Rebound Therapeutics's valuations in December 2015 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/9/2019

Acquired

0

FY undefined

4

7/25/2017

Series B

$99M

$44.45M

0

FY undefined

10

12/31/2015

Series A

$99M

$99M

0

FY undefined

10

Date

9/9/2019

7/25/2017

12/31/2015

Round

Acquired

Series B

Series A

Amount

$99M

$99M

Investors

Valuation

$44.45M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

4

10

10

Rebound Therapeutics Deal Terms

2 Deal Terms

Rebound Therapeutics's deal structure is available for 2 funding rounds, including their Series B from July 25, 2017.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Rebound Therapeutics Investors

4 Investors

Rebound Therapeutics has 4 investors. Integra LifeSciences invested in Rebound Therapeutics's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/9/2019

9/9/2019

1
Acquired

Corporation

New Jersey

00/00/0000

00/00/0000

HBM Healthcare Investments

Subscribe to see more

Venture Capital

Switzerland

00/00/0000

00/00/0000

Invus Group

Subscribe to see more

Asset/Investment Management

New York

00/00/0000

00/00/0000

Wexford Capital

Subscribe to see more

Private Equity

Connecticut

First funding

9/9/2019

00/00/0000

00/00/0000

00/00/0000

Last Funding

9/9/2019

00/00/0000

00/00/0000

00/00/0000

Investor

HBM Healthcare Investments

Invus Group

Wexford Capital

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Asset/Investment Management

Private Equity

Location

New Jersey

Switzerland

New York

Connecticut

Rebound Therapeutics Portfolio Exits

1 Portfolio Exit

Rebound Therapeutics has 1 portfolio exit. Their latest portfolio exit was Viseon Spine on January 01, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/1/2017

Spinoff / Spinout

Viseon Spine

$99M

1

Date

1/1/2017

Exit

Spinoff / Spinout

Companies

Viseon Spine

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.